Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $14,329,623.00 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 151,300 shares of the business’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $94.71, for a total value of $14,329,623.00. Following the completion of the transaction, the chief executive officer directly owned 774,500 shares in the company, valued at approximately $73,352,895. This represents a 16.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $93.86 on Monday. The company has a market cap of $7.32 billion, a price-to-earnings ratio of 72.20 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 12-month low of $37.02 and a 12-month high of $98.48. The firm’s 50-day simple moving average is $80.46 and its 200 day simple moving average is $61.36.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. On average, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently made changes to their positions in KNSA. Allworth Financial LP increased its stake in Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after purchasing an additional 134 shares in the last quarter. Arizona State Retirement System raised its holdings in Kiniksa Pharmaceuticals International by 2.1% in the second quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after purchasing an additional 209 shares during the period. GAMMA Investing LLC raised its holdings in Kiniksa Pharmaceuticals International by 21.1% in the third quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock worth $95,000 after purchasing an additional 223 shares during the period. Commonwealth Equity Services LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock worth $811,000 after purchasing an additional 237 shares in the last quarter. Finally, First Trust Advisors LP boosted its position in shares of Kiniksa Pharmaceuticals International by 3.1% during the first quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after purchasing an additional 293 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on KNSA. JPMorgan Chase & Co. boosted their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. The Goldman Sachs Group raised their price target on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Finally, Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $100.57.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally.

Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

The company also develops investigational therapies for inflammatory and immune-mediated conditions, including treatments that target pathways involved in immune-cell activity.